These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 8425019

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Didanosine: long-term follow-up of patients in a phase 1 study.
    Lambert JS, Seidlin M, Valentine FT, Reichman RC, Dolin R.
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S40-5. PubMed ID: 8093846
    [Abstract] [Full Text] [Related]

  • 52. Rates and risk factors for adverse events associated with didanosine in the expanded access program.
    Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L.
    Clin Infect Dis; 1994 Dec; 19(6):1076-83. PubMed ID: 7888537
    [Abstract] [Full Text] [Related]

  • 53. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
    Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A.
    Cochrane Database Syst Rev; 2000 Dec; (3):CD002038. PubMed ID: 10908523
    [Abstract] [Full Text] [Related]

  • 54. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Dec; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 55. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
    Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF.
    J Infect Dis; 1996 Jun; 173(6):1354-66. PubMed ID: 8648207
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
    Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, Cort S, Sullivan JL.
    N Engl J Med; 1997 May 08; 336(19):1343-9. PubMed ID: 9134874
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.
    Yarchoan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, Hartman N, Johns DG, Broder S.
    Lancet; 1990 Sep 01; 336(8714):526-9. PubMed ID: 1975038
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.